Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2005-11-08
2005-11-08
Jones, Dameron L. (Department: 1616)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001110, C424S001650, C424S001730
Reexamination Certificate
active
06962686
ABSTRACT:
A delivery vehicle is described that is capable of being specifically bound to and taken into targeted cells, delivering numerous physiological agents, particularly paramagnetic ions for magnetic resonance imaging (MRI) of the cells. The delivery vehicle comprises a polymeric molecule having a net positive charge complexed with another polymeric molecule having a net negative charge. Cell targeting moieties and physiological agents, including contrast agents and therapeutic agents, are attached to one or both of the polymeric molecules. In one embodiment, the polymeric molecule having a net negative charge is a nucleic acid. Thus, the delivery vehicles can be used in clinical protocols in which nucleic acids for gene therapy and agents for MRI contrast are co-transported to specific cells allowing medical imaging monitoring of nucleic acid delivery.
REFERENCES:
patent: 4104466 (1978-08-01), Tsuchida et al.
patent: 4284537 (1981-08-01), Beachey
patent: 4701521 (1987-10-01), Ryser et al.
patent: 4847240 (1989-07-01), Ryser et al.
patent: 5059415 (1991-10-01), Neuwelt
patent: 5155215 (1992-10-01), Ranney
patent: 5230883 (1993-07-01), Kornguth et al.
patent: 5241060 (1993-08-01), Engelhardt et al.
patent: 5274119 (1993-12-01), Frazier et al.
patent: 5358704 (1994-10-01), Desreux et al.
patent: 5373093 (1994-12-01), Vallarino et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 0253202 (1988-01-01), None
patent: 0388758 (1990-09-01), None
patent: 9301837 (1993-02-01), None
Wagner et al (1990), Proc. Natl. Acad. Sci. USA, vol. 87, pp. 3410-3414, Transferrm-Polycation Conjugates as Carriers for DNA Uptake.
Wogner et al(1991), Proc.Natl.Acad. Sci. USA, vol. 88,pp. 4255-4259, “Transferrin-Polycation-DNA Complexes: The Effect of Polycations on the Structure of the Complex and DNA Delivery to Cells.”
Panday et al (1986). Journal of Immunological Methods, vol. 94, pp. 237-246, “Photo-Chemical Linking of Primary Aromatic Amines to Carrier Proteins to Elicit Antibody Response Against the Amine Haptens.”
Hratowich et al (1983), Journal of Immunoogical Methods, vol. 65, pp. 147-157, “The Preparation of DTPA-Coupled Antibodies Radiolabeled With Metallic Radonuclides: an Improved Method”.
Cotton et al (Jun. 1990), Proc. Natl. Acad. Sci. USA, vol. 87, pp. 4033-4037, “Transferrin-Poly Cation-Mediated Introduction of DNA into Human Leukemic Cells: Stimulation by Agents That Affect the Survival of Transfected DNA or Modulate Transferrin Receptor Levels.”
Wu et al. J. Biol. Chem., 226(22):14338-14342, 1991.
Diwu, Z. And J. W. Lown, “Phototherapeutic Potential of Alternative Photosensitizers to Porphyrins,”Pharmac. Ther., 63:1-35 (1994).
Goldenberg, D.M., et al., “Targeting Cancer wit Radiolabeled Antibodies,” 5th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, N.J., USA (Oct. 6-8, 1994).
Grossweiner, L.I., “Photodynamic Therapy with Porphyrin Derivatives,”Porphyric Pesticides, Ch. 18 255-265 (1994).
Hung,M-C., et al., “HER-2/Neu-Targeting Gene Therapy—a Review,”Gene, 159:65-71 (1995).
Kayyem, J.F., et al., “Receptor-Targeting Co-Transport of DNA and Magnetic Resonance Contrast Agents,”Chemistry&Biology, 2:615-620 (1995).
Kemshead, J.T., and K. Hopkins, “Uses and Limitations of Monoclonal Antibodies (MoAbs) in the Treatment of Malignant Disease: A Review,”Journal of the Royal Society of Medicine, 86:219-224 (1993).
King, D.J., et al., “Improved Tumor Targeting with Chemically Cross-Linked Recombinant Antibody Fragments,”Cancer Research, 54:6176-6185 (1994).
Larson, S.W., “Radioimmunology,”Cancer, 67:1253-1260 (1991).
Ludlow, J.W. and G.R. Skuse, “Viral Oncoprotein binding to pRB, p107, p130, and p300,”Virus Research, 35:113-121 (1995).
Schott, M.E., et al., “Biodistribution and Preclinical Radioimmunotherapy Studies Using Radiolanthanide-Labeled Immunoconjugates,”Cancer, 73(3):993-998 (1994).
Jurcic, J.G. and Scheinberg, D.A., “Recent Developments in the Radioimmunotherapy of Cancer,”Current Opinion in Immunology, 6:715-721 (1994).
Thomas, H., and Sikora, K., “New Therapeutic Modalities for Cancer,”Reviews in Oncology, 4(1):107-120 (1991).
Uckun, F.M., et al., “Biotherapy of B-Cell Precursor Leukemia by Targeting Genistein to CD19-Associated Tyrosine Kinases,”Science, 267:886-891 (1995).
Uckun, F.M., “Immunotoxins for the Treatment of Leukaemia,”British Journal of Haematology, 85:435-438 (1993).
Urban, J.L., “Tumor Antigens,”Annu. Rev. Immunol., 10:617-644 (1991).
Wilbur, D.S., et al., “Monoclonal Antibody Fab' Fragment Cross-Linking Using Equilibrium Transfer Alkylation Reagents. A Strategy for Site-Specific Conjugation of Diagnostic and Therapeutic Agents with F(ab')2Fragments,”Bioconjugate Chem., 5:220-235 (1994).
Wagner, E., et al., “Influenza Virus Hemagglutinin HA-2 N-Terminal Fusogenic Peptides Augment Gene Transfer by Transferrin-Polylysine-DNA Complexes: Toward a Synthetic Virus-Like Gene-Transfer Vehicle,”Proc. Natl. Acad. Sci. USA, 89:7934-7938 (1992).
Wu, C., et al., “Metal-Chelate-Dendrimer-Antibody Constructs for Use in Radioimmunotherapy and Imaging,”Bioorganic and Medicinal Chemistry Letters, 4(3):449-454 (1994).
Wu, G.W., et al., “Receptor-Mediated Gene Delivery in Vivo,”J. Biol. Chem., 266(22):14338-14342 (1991).
Kumar, K., et al., “Ligand Basicity and Rigidity Control Formation of Macrocyclic Polyamino Carboxylate Complexes of Gadolinium (III)”,Inorg. Chem., 32:4193-4199 (1993).
Lex, L., “Development of Contrast Enhancing Agents in Magnetic Resonance Imaging,”Acta Biochim. Biophys. Hun., 24/3:265-281 (1989).
Grossweiner, L.I., “Photodynamic Therapy with Porphyrin Derivatives,”American Porphyric Pesticides, Ch. 18:225-265 (1994).
Paajanen, H., et al., “Proton Relaxation Enhancement of Albumin, Immunoglobulin G, and Fibrinogen Labeled with Gd-DTPA,”Magnetic Resonance in Medicine, 13:38-43 (1990).
Behr, Jean-Paul, “Gene Transfer with Synthetic Cationic Amphiphiles: Prospects for Gene Therapy,”Bioconjugate Chem., 5:382-389 (1994).
Schwendener, R.A., “Liposomes and Immunoliposomes as Carriers for Cytostatic Drugs, Magnetic Resonance Contrast Agents, and Fluorescent Chelates,”Chimia, 46:69-77 (1992).
Zatloukal, K., et al., “Somatic Gene Therapy for Cancer: The Utility of Transferrinfection in Generating ‘Tumor Vaccines’,”Gene, 135:199-207 (1993).
DeMagalhaes-Silverman, M., et al., “Bone Marrow Transplantation a Review,”Cell Transplantation, 2:75-98 (1993).
Gutierrez, A.A., et al., “Gene Therapy for Cancer,”The Lancet, 339:715-721 (1992).
Renn, O., et al., “Large-Scale Synthesis of the Bifunctional Chelating Agent 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″ -tetraacetic Acid, and the Determination of Its Enantiomeric Purity by Chiral Chromatography,”Bioconjugate Chem., 3:563-569 (1992).
McMurray, T.J., et al., “Convenient Synthesis of Bifunctional Tetraaza Macrocycles,”Bioconjugate Chem., 3:108-117 (1992).
Moi, M.K., et al., “The Peptide Way to Macrocyclic Bifunctional Chelating Agents: Synthesis of 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″,-tetraacetic Acid and Study of Its Yttrium (III) Complex,”J. Am. Chem. Soc., 110:6266-6267 (1988).
Tweedle, M.F., et al., “Considerations Involving Paramagnetic Coordination Compounds as Useful NMR Contrast Agents,”Nucl. Med. Biol., 15(1):31-36 (1988).
Cotten, M., et al., “High-Efficiency Receptor-Mediated Delivery of Small and Large (48 Kilobase Gene Constructs Using the Endosome-Disruption Activity of Defective or Chemically Inactivated Adenovirus Particles,”Proc. Natl. Acad Sci, USA., 89
Fraser Scott E.
Kayyem Jon F.
Meade Thomas J.
California Institute of Technology
Dorsey & Whitney LLP
Jones Dameron L.
Silva Robin M.
Trecartin Richard F.
LandOfFree
Cell-specific gene delivery vehicles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell-specific gene delivery vehicles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-specific gene delivery vehicles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3476315